| Gene symbol | CD276 | Synonyms | 4Ig-B7-H3, B7-H3, B7H3, B7RP-2 | Type of gene | protein-coding |
| Chromosome | 15 | Map location | 15q24.1 | dbXrefs | |
| Description | CD276 molecule | ||||
| GTO ID | GTC3928 |
| Trial ID | NCT06482905 |
| Disease | High Grade Glioma |
| Altered gene | CD276 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | TX103 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A Phase I, Open-Label, Single/Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Antitumor Activity of TX103 CAR-T Cell Injection (TX103) in Subjects With Recurrent or Progressive Grade 4 Glioma. |
| Year | 2024 |
| Country | China |
| Company sponsor | Tcelltech Inc. |
| Other ID(s) | TX103T-RG008 |
| Cohort 1 | |||||||||
|
|||||||||